SEC Form 4 · accession 0001470831-26-000689
C4 Therapeutics, Inc. · CCCC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donna Roy Grogan
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 4:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001662579
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 1, 2026 | A | 3,341 | $4.34 | A | 74,853 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
- F2The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2026.